Abstract:Dermal fibrosis is characterized by the activation of the matrix-producing 'positive' myofibroblasts, and the relentless production and deposition of extracellular matrix. The hedgehog pathway has recently been demonstrated to work in a pro-fibrotic manner in systemic sclerosis (SSc). A negative regulator of the hedgehog pathway (Hh), the suppressor of fused (Sufu), was shown to be involved in the activation of fibrotic diseases. However, the exact role of Sufu in fibrosis has not been investigated so far. In our study, we aimed to define the role of sufu in the process of fibrosis using dermal fibroblasts of healthy donors that were cultured in vitro. Cyclopamine, a Smo antagonist, and Sufu lentivector were used to treat or transfect cells. The expression of fibrosis markers and ERK1/2, Smad2, and GSK3β at the protein level was determined by Western blot. Fibroblast migration was measured by in vitro wound healing assay. Bleomycin-induced dermal fibrosis mouse model was introduced to assess the effect of cyclopamine on dermal fibrosis in vivo. We found that cyclopamine significantly upregulated the expression of Sufu. Both cyclopamine and Sufu lentivector reduced migration and myofibroblast differentiation of human dermal fibroblasts at a statistically significant level. Furthermore, cyclopamine reversed dermal fibrosis induced by TGF-β1. Cyclopamine and the overexpression of Sufu inhibited the phosphorylation of GSK-3β and restrained the migration of fibroblasts. Dermal fibrosis was inhibited by intraperitoneal injection of cyclopamine in a mouse model of scleroderma. Our findings suggest that cyclopamine and Sufu-overexpression may effectively inhibit the endogenous as well as the TGF-β1-induced activation of fibroblasts through subsequent activation of GSK-3β. Sufu agonists may be a promising approach in the development of antifibrotic medications for dermal fibrosis and systemic sclerosis.

Members of the Rusc Protein Family Interact with Sufu and Inhibit Vertebrate Hedgehog Signaling.

Differential regulation of Gli proteins by Sufu in the lung affects PDGF signaling and myofibroblast development.

Suppressor of Fused inhibits mammalian Hedgehog signaling in the absence of cilia.

Cilium-independent Regulation of Gli Protein Function by Sufu in Hedgehog Signaling is Evolutionarily Conserved.

Structural Insight into the Mutual Recognition and Regulation Between Suppressor of Fused and Gli/Ci.

Dual function of suppressor of fused in Hh pathway activation and mouse spinal cord patterning.

Molecular mechanisms of suppressor of fused in regulating the hedgehog signalling pathway (Review)

Inhibition of the Transcription Factor ZNF281 by SUFU to Suppress Tumor Cell Migration

Antagonistic and Cooperative Actions of Kif7 and Sufu Define Graded Intracellular Gli Activities in Hedgehog Signaling.

Dual Regulatory Functions of SUFU and Targetome of GLI2 in SHH Subgroup Medulloblastoma.

Nek2a/Sufu Feedback Loop Regulates Gli-Mediated Hedgehog Signaling Pathway

Negative regulation of Gli1 and Gli2 activator function by Suppressor of fused through multiple mechanisms

Hedgehog signaling pathway member SuFu in colorectal cancer

Hedgehog signaling is controlled by Rac1 activity

Nek2A Phosphorylates and Stabilizes SuFu: A New Strategy of Gli2/Hedgehog Signaling Regulatory Mechanism.

MEKK2 and MEKK3 Suppress Hedgehog Pathway-Dependent Medulloblastoma by Inhibiting GLI1 Function

Structural Insight into the Recognition Between Sufu and Fused in the Hedgehog Signal Transduction Pathway.

SCF (Fbxl17) ubiquitylation of Sufu regulates Hedgehog signaling and medulloblastoma development

Hedgehog signaling downregulates Suppressor of Fused through the HIB/SPOP-Crn axis in Drosophila

Suppressor of Fused Inhibits Skin Wound Healing

Inhibition of the Hedgehog Pathway Leads to Antifibrotic Effects in Dermal Fibrosis